Anti-CD20 monoclonal antibodies are utilized to deplete B cells and were originally designed to treat B cells proliferative diseases, such as non-Hodgkin’s Lymphoma as well as chronic lymphocytic leukemia. You can visit www.bosterbio.com/anti-cd20-ms4a1-picoband-trade-antibody-a03780-3-boster.html to know more about cd20 antibodies-online.
Image Source: Google
Anti-CD20 was later evaluated and applied to treating the autoimmune disease rheumatoid arthritis due to the premise that the elimination of the autoantibody-producing or T cell-activating cells from B cells will result in improvement in clinical outcomes.
The clinically evident benefits of using anti-CD20 mAbs in RA especially those who are not responding to other treatments has resulted in the development of anti-CD20 mAbs for other autoimmune disorders that have both T cell and B cell etiologies, such as systemic lupus and erythematosus (SLE) and MS. (MS ).
CD20 is a transmembrane calcium channel that is involved in B cells’ proliferative, activation and differentiation. It is found on the B cell surface in the pre-B cell stage and later maturing memory B cell phases.
Anti-CD20 mAbs are aimed at B cells at this phase of development, while preserving the early pre-B cells as well as plasma cells, thereby preserving long-term immune memory as well as B cell reconstitution after the depletion.
The latest generation of anti-CD20 mAbs, which are either humanized or fully human, have been created in recent times to tackle the issue of immunogenicity.
To increase efficacy, a number of the anti-CD20 mAbs that are second-generation are more binding affinities for their Fc receptor of B cells as well as an increase in the cytotoxicity of complement-dependent (CDC) or antibody-dependent cellular toxicity (ADCC).
